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Objective: To evaluate the factors associated with plasma concentrations of atazanavir (ATV)
in  a cohort of well-controlled HIV infected subjects (undetectable viremia).
Design:  Cross-sectional study where 69 subjects were consecutively enrolled between April
and  November, 2011.
Methods:  Patients had to be on atazanavir for at least six months, undetectable viral load
for  a period equal to or longer than 12 months, T CD4+ lymphocyte count higher than
200  cells/mm3, and aged between 18 years and 70 years old. Exclusion criteria were preg-
nancy,  any neurologic disease, active opportunistic disease, hepatitis or cancer. Atazanavir
plasma  levels were measured by ultra-performance liquid chromatography.
Results  and discussion: Overall, 54 patients (mean age of 47 years and 50% women) were
included  in the analysis. Those without ritonavir (unboosted atazanavir) had statistically
lower  plasma concentrations than those with ritonavir boosted atazanavir (p = 0.001) and
total  and indirect bilirubin were statistically associated with plasma concentration of
atazanavir (r = 0.32 and r = 0.33 respectively; p < 0.05 in both cases). No statistical associa-
tion  was found among gender, ethnicity, age, weight, body mass index (BMI), lipid proﬁle,
and  the plasma concentration of atazanavir.
Conclusion: In summary, as expected, concomitant ritonavir use was the only factor asso-ciated  with atazanavir plasma levels. Prospective studies with a larger sample size might
help  to observe an association of atazanavir concentrations to other characteristics such as
body weight, since the p-value showed to be close to signiﬁcance (p = 0.068).
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Introduction
The introduction of highly active antiretroviral therapy
(HAART) as the standard of care in HIV infection dramatically
decreased mortality rates in such individuals.1,2 However,
antiretroviral therapy (ART) may  be associated, in the medium
and  long run, to the development of important side effects,
such  as insulin-resistance, type-2 diabetes mellitus (DM),
hypertension, dyslipidemia, central obesity, metabolic syn-
drome,  and nephrotoxicity.3–8
Atazanavir (ATV), which is typically administered with
low-dose ritonavir (/r), has been an important innovation
in  the treatment of adult HIV infection owing to its ease
of  dosing, virologic potency, and minimal metabolic toxic-
ity  (such as lower effect on lipid and glucose metabolism).
Some limitations to this drug are potential interactions
with acid-reducing agents and those increased by the use
of  ritonavir low-dose, such as benign hyperbilirubinemia
with jaundice, and nephrotoxicity (including the risk of
nephrolithiasis).9
In that context, higher plasma levels of the drug is one
of  the key factor that might contribute to the develop-
ment of toxicity.10,11 Therapeutic drug monitoring can be
a  useful weapon for dose adjustment in order to avoid
concentrations that are out of the therapeutic range, thus
preventing toxicity.5,12,13 The purpose of this study was  to
assess  the factors associated with plasma concentrations
of ATV in HIV infected individuals with undetectable viral
load  in order to try to prevent toxicities attributed to this
drug.
Materials  and  methods
Study  population
Between April and November 2011 patients receiving care
at  the HIV/AIDS Outpatient Clinic of Hospital de Clínicas de
Porto  Alegre (HCPA), Brazil were consecutively enrolled in the
study.  Patients had to be on ATV for at least six months, with
undetectable viral load (<50 copies/mL) for a period equal to
or  longer than 12 months, with T CD4+ lymphocyte count
higher  than 200 cells/mm3 and aged between 18 and 70 years
old.  Subjects with neurological conditions who were not able
to  understand the study, with active opportunistic disease,
with  hepatitis, with any type of active known neoplasia, and
pregnant  women  were excluded from the study. The study
was  approved by the HCPA Ethics Review Board (ERB), and all
patients  signed the informed consent.
Data  collection
A questionnaire was  administered for collecting additional
information such as comorbidities, concurrent medications,
time  on ATV, time of last dose of ATV, ART regimen used,
adverse  effects reported by the patient, and adherence
to treatment. Body weight, height and body mass index
(BMI)  were  obtained when the patient was  included in the
study. 1 3;1  7(6):657–660
Sample  collections
The blood samples collected by venipuncture for analyzing
ATV  plasma concentrations were stored in EDTA-containing
tubes. The tubes were centrifuged at 2500 rpm at 4 ◦C for
10  min  and the resulting plasma was placed in a properly num-
bered  Eppendorf tube and immediately stored at −80 ◦C until
determination of ATV plasma concentration. The researchers
who  measured the plasma concentrations of the drug were
blind  to the subjects’ variables.
Determination  of  ATV  plasma  concentrations
Ultra performance liquid chromatography (UPLC) with diode
array  detection was  the method used to determine ATV
plasma  concentrations.11 After the liquid–liquid extraction
of  0.5 mL  of plasma with methyl-tert-butyl ether, the ana-
lytes  were separated on a ACQUITY UPLC BEH® C18 column
(2.1  mm × 150 mm,  p.d. 1.7 m)  eluted with a gradient of tri-
ethylammonium phosphate buffer pH 3.0 and acetonitrile.
Total running time was  9.5 min. Calibration curves were  linear
in  the range of 0.1–10.0 g/mL. The lower limit of quantitation
was  0.1 g/mL for ATV. Accuracy ranged from 94.9 to 103.5%.
Both  interday and intraday coefﬁcients of variation were  less
than  7.7% for all analytes. Extraction yields were  greater than
88.2%.
Statistical  analysis
Pearson correlation was  used to measure the association
between plasma concentrations of ATV and variables. Stu-
dent’s  t test was  performed to assess whether there was
statistical difference in plasma concentrations of ATV related
to  RTV in antiretroviral regimen. The correlation between ATV
concentration and time of the last dose of this drug was
evaluated using Sperman’s rank correlation. As there was no
association between these variables (data not shown), all sub-
jects  were  included in the analyses. Logarithmic and reverse
transformations were used for the variables treated as non-
parametric  data. We  used a signiﬁcance level of 5% for all tests.
The  statistical analysis was performed at the SPSS program,
version  19.0.
Results
From 150 screened patients, 69 agreed to be enrolled in the
study.  Out of these, 15 (22%) were  excluded: ﬁve because they
did  not come at the time of blood collection; and 10 for not
presenting concomitant laboratory tests. Table 1 shows the
demographic  data of the remaining 54 patients (27 females;
5  Afro-descendents) included in the analyses. The overall
mean  age (±SD) was  46.7 (±10.7) years. Besides ATV with
(n  = 42) or without (n = 12) ritonavir (RTV), the other compo-
nents  of HAART were:  zidovudine + lamivudine (3TC) (n = 30);
tenofovir  + 3TC (n = 19); abacavir + 3TC (n = 3); and other com-
binations  (n = 2). No patient was  taking any medication that
could  interfere with gastric pH (such as antacids or proton
pump  inhibitors).
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Table 1 – Demographic, treatment and biochemical data
of  the study sample of 54 individuals infected with HIV.
n Mean ± SD or as
indicated
Gender (%)
Female 27 50
European-descendent (%) 49 90.7
Age (years) 54 46.7 ± 10.7
Body weight (kg) 54 67.0 ± 10.5
BMI (kg) 54 25.1 ± 3.24
Time on ATV (months) 54 53 ± 25
Total cholesterol (mg/dL)a 50 191.5 ± 37.0
HDL cholesterol (mg/dL)a 50 40.0 ± 10.8
LDL cholesterol (mg/dL)a 46 113.7 ± 31.6
Triglycerides (mg/dL)a 48 188.2 ± 112.0
Glucosea 43 112.5 ± 45.5
Total bilirubin (mg/dL) 54 1.48 ± 0.93
Indirect bilirubin (mg/dL) 54 1.95 ± 1.19
Plasma concentration of ATV (ng/mL) 54 1399.0 ± 1359.9
Use of RTV (%) 42 78
ATV, atazanavir; RTV, ritonavir; SD, standard deviation; BMI, body
mass index.
a Some patients did not have results concomitant with the date of
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We  found no association among gender, ethnicity, age,
eight  and BMI  and ATV plasma concentration (p > 0.07)
Table  2), as we  also did not observe any relationship with
ime  on ATV (p = 0.688). Lipid proﬁle was  also not asso-
iated with the plasma concentration of ATV (p = 0.190).
owever, as expected, total and indirect bilirubin were statis-
ically  associated with plasma concentration of ATV (r = 0.32
nd  r = 0.33 respectively; p < 0.05 in both cases) (Table 2).
lso  plasma concentration of ATV was  statistically higher
Table 2 – Association between demographic and other variable
Variable Descriptor
concen
coefﬁcie
Gender Female:  130
Male:  1494.8
Ethnicity European-d
African-des
Age (years) r = 0.195 
Body weight (kg) r = −0.250 
BMI (kg) r = −0.220 
Time on ATV (months) r = 0.056 
Total cholesterol (mg/dL) r = −0.014 
HDL cholesterol (mg/dL) r = −0.165 
LDL cholesterol (mg/dL) r = −0.064 
Triglycerides (mg/dL) r = 0.192 
Glucose (mg/dL) r = −0.092 
Total bilirubin (mg/dL) r = 0.321 
Indirect bilirubin (mg/dL) r = 0.334 
ATV concentration (ng/mL) ATV 400 mg
ATV 300 mg
ATV, atazanavir; RTV, ritonavir; SD, standard deviation; BMI, body mass ind
a Between transformed variables when appropriate.
b The mean difference is signiﬁcant at the p-value = 0.05.3;1 7(6):657–660  659
(p = 0.001) in the group using ATV 300 mg  daily combined
with RTV (mean ± SD: 1623.9 ± 1435.6 ng/mL; n = 42) than in the
group  using ATV 400 mg  daily, without the addition of RTV
(1623.9  ± 1435.6 ng/mL; n = 12).
Discussion
In our study plasma concentrations of ATV was  associated
with  the use of RTV as a component of HAART. Half of our
sample  included women which allowed us to compare plasma
levels  between genders. In our study, there was no difference
between males and females in regard to ATV concentrations.
Likewise, age had no inﬂuence on ATV plasma concentra-
tions. These ﬁndings are in line with the ﬁndings of Hentig
et  al.,14 who found that ATV/r pharmacokinetics were similar,
irrespective of demographic parameters.
Unlike other antiretroviral drugs such as EFZ, the plasma
concentration of ATV does not change signiﬁcantly with body
weight,  as shown in our study (p = 0.068).5 Nevertheless, our
limited  sample size could have affected this result.
According to the literature, ATV has few effects on serum
lipids  and it is considered to have a safe metabolic proﬁle.9,15
In our study we  were able to show not only that patients did
not  present dyslipidemia, but also that ATV plasma concen-
trations  had no correlation with serum lipid levels.
This study has some limitations. Collection time was  not
standardized considering the time when the last dose of
ATV  had been taken. In order to try to minimize this issue,
time  after last ATV dose and plasma concentration was  stud-correlation between time of ATV last dose and its plasma con-
centration  (r = −0.177; p = 0.233). This ﬁnding may  suggest that
blood  time collection in these patients did not inﬂuence ATV
s with ATV plasma concentration (n = 54).
s (mean ± SD of the ATV
tration  or correlation
nt between variablesa)
p
3.2 ± 1200.9 ng/mL
 ± 1519.4 ng/mL 0.609
escent:  1485.8 ± 1392.8 ng/mL
cent: 548.6 ± 479.8 ng/mL 0.144
0.158
0.068
0.110
0.688
0.924
0.251
0.673
0.190
0.559
0.018b
0.019b
: 611.8 ± 600.1 ng/mL
/RTV: 1623.9 ± 1435.6 ng/mL 0.001b
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plasma levels. This result could reﬂect the steady-state of ATV
in the study subjects, i.e., drug plasma concentration vari-
ability  in samples collected close to the nadir (through) did
not  signiﬁcantly differ from that collected close to the peak
or  the midpoint of the drug administration interval. Lastly,
ﬁve  patients (10.2%) had no detectable ATV levels. This ﬁnd-
ing  was  not related to the time since the last pill had been
taken  and might actually reﬂect that the patients included in
the analysis did not give us the right information. We  were
also  concerned about the accuracy of our data. Therefore we
tested  the association between ATV plasma concentration and
bilirubin  measurements. As expected, we found a positive
relationship (p < 0.001) which strengthened the validity of our
information.16
In summary, in this study we  found that only RTV use to
be  associated with ATV plasma levels. Larger studies might
further  evaluate the possible role of other factors that would
probably  inﬂuence drug plasma levels (such as weight and
age).
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